Health Evaluating Novo Nordisk’s CagriSema in the Weight-Loss Race Against Lilly’s ZepboundBy Sam Allcock20 December 2024 Novo Nordisk has introduced its combination drug, CagriSema, in a recent major trial to challenge Eli Lilly’s Zepbound. This long-standing…
